Generic Name and Formulations:
Granisetron (as HCl) 1mg/5mL; soln; orange-flavor.
Indications for GRANISOL:
Prevention of nausea and vomiting associated with chemotherapy (including high-dose cisplatin) or with radiation (including total body irradiation and fractionated abdominal radiation).
Chemotherapy: give only on the days chemo is given. 2mg once daily up to 1 hour before chemo; or, 1mg up to 1 hour before chemo, then 1mg 12 hours after 1st dose. Radiation: 2mg once daily within 1 hour of radiation.
Pre-existing arrhythmias or cardiac conduction disorders. Increased risk of QT prolongation: cardiac disease, on cardio-toxic chemotherapy, electrolyte abnormalities and/or concomitant drugs that prolong the QT interval. Abdominal surgery. May mask progressive ileus and/or gastric distention. Pregnancy (Cat.B). Nursing mothers.
Caution with drugs that affect CYP450 or drugs known to prolong the QT interval and/or are arrhythmogenic.
Selective 5-HT3 receptor antagonist.
Headache, asthenia, diarrhea, constipation, abdominal pain; QT prolongation.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|